Lachnospira is a signature of antihistamine efficacy in chronic spontaneous urticaria

Liu, Runqiu; Peng, Cong; Jing, Danrong; Xiao, Yangjian; Zhu, Wu; Zhao, Shuang; Zhang, Jianglin; Chen, Xiang; Li, Jie

doi:10.1111/exd.14460

Cited by 18 publications

(11 citation statements)

References 24 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lachnospira belongs to Clostridiales and has been found to be a microorganism that produces SCFAs. One study found that Lachnospiraceae and its subgroups were the major differences in gut microbiota between antihistamine responders and non-responders in CSU patients, with Lachnospira more abundant in antihistamine responders than non-responders ( Liu et al., 2022 ). Our study did not distinguish between the efficacy of antihistamines in patients, so further studies are needed to address the increased abundance of Lachnospira in our study.…”

Section: Discussionmentioning

confidence: 99%

Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria

Luo

Jin²,

Tao³

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundThe pathogenesis of chronic spontaneous urticaria (CSU) is unclear, and it turned out to be involved in biological processes, such as autoimmunity, autoallergy, inflammation, and coagulation. The gut microbiota plays an important role in immune and inflammatory diseases. However, the relationship between chronic spontaneous urticaria and the gut microbiota remains unknown.MethodsThe stool and serum samples were taken from 15 CSU patients and 15 normal controls. Changes in the composition of gut microbiota and serum metabolism in CSU patients and normal controls were analyzed by 16S ribosomal RNA (rRNA) gene sequencing and untargeted metabolomics.ResultsThe results of 16S rRNA gene sequencing showed that compared with normal controls, CSU patients had increased α-diversity of gut microbiota and significant differences in β-diversity. At the phylum level, the relative abundance of Firmicutes increased and the relative abundance of Bacteroidetes and Proteobacteria decreased in CSU patients compared with healthy controls. At the genus level, six kinds of bacteria were significantly enriched in CSU patients and five in normal controls. Metabolomic analysis revealed altered levels of metabolites such as unsaturated fatty acids and purines. Correlation analysis of gut microbiota and metabolites showed that Lachnospira was negatively correlated with arachidonic acid, and Gemmiger was also negatively correlated with (±)8-HETE.ConclusionThis study suggests that changes in gut microbiota and metabolites may play a role in immune and inflammatory pathways in the pathogenesis of CSU patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria

Luo

Jin²,

Tao³

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Moreover, the correlation analysis between gut microbiota and metabolites revealed their relationship, thus further elucidating the pathogenesis of pyroitinib-induced diarrhea and the mechanism of SBP treatment [ 48 , 49 ]. For example, given that Lachnospiraceae , a strain closely associated with diarrhea, which is found in the gut of most healthy people, could be a potentially beneficial bacterium [ 50 ]. We hypothesized that Lachnospiraceae might be involved in the mechanism of SBP in the treatment of pyrrotinib-induced diarrhea by affecting the metabolism of 25-hydroxycholesterol, guanidinosuccinic acid, and 5-hydroxyindolepyruvate.…”

Section: Discussionmentioning

confidence: 99%

Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology

et al. 2022

View full text Add to dashboard Cite

Background Shenling Baizhu Powder (SBP) is a traditional Chinese medicine (TCM) prescription, which has the good efficacy on gastrointestinal toxicity. In this study, we used gut microbiota analysis, metabonomics and network pharmacology to investigate the therapeutic effect of SBP on pyrotinib-induced diarrhea. Methods 24 Rats were randomly divided into 4 groups: control group, SBP group (3.6 g/kg /bid SBP for 10 days), pyrotinib model group (80 mg/kg/qd pyrotinib) and pyrotinib + SBP treatment group. A 16S rRNA sequencing was used to detect the microbiome of rat fecal bowel. Metabolic profiles were collected by non-targeted metabolomics and key metabolic pathways were identified using MetaboAnalyst 5.0. The antitumor effect of SBP on cells treated with pyrotinib was measured using a CCK-8 assay. Network pharmacology was used to predict the target and action pathway of SBP in treating pyrotinib-related diarrhea. Results In vivo study indicated that SBP could significantly alleviate pyrotinib-induced diarrhea, reaching a therapeutic effect of 66.7%. SBP could regulate pyrotinib-induced microbiota disorder. LEfSe research revealed that the SBP could potentially decrease the relative abundance of Escherichia, Helicobacter and Enterobacteriaceae and increase the relative abundance of Lachnospiraceae, Bacilli, Lactobacillales etc. In addition, 25-Hydroxycholesterol, Guanidinosuccinic acid, 5-Hydroxyindolepyruvate and cAMP were selected as potential biomarkers of SBP for pyrotinib-induced diarrhea. Moreover, Spearman's analysis showed a correlation between gut microbiota and metabolite: the decreased 25-hydroxycholesterol in the pyrotinib + SBP treatment group was negatively correlated with Lachnospiraceae while positively correlated with Escherichia and Helicobacter. Meanwhile, SBP did not affect the inhibitory effect of pyrotinib on BT-474 cells and Calu-3 cells in vitro. Also, the network analysis further revealed that SBP treated pyrotinib-induced diarrhea through multiple pathways, including inflammatory bowel disease, IL-17 signaling pathway, pathogenic Escherichia coli infection and cAMP signaling pathway. Conclusions SBP could effectively relieve pyrotinib-induced diarrhea, revealing that intestinal flora and its metabolites may be involved in this process.

show abstract

“…Moreover, the correlation analysis between gut microbiota and metabolites revealed their relationship, thus further elucidating the pathogenesis of pyroitinib-induced diarrhea and the mechanism of SBP treatment [45,46]. For example, given that Lachnospiraceae, a strain closely associated with diarrhea, which is found in the gut of most healthy people, could be a potentially bene cial bacterium [47]. We hypothesized that Lachnospiraceae might be involved in the mechanism of SBP treatment of pyrrotinib-induced diarrhea by affecting the metabolism of 25-hydroxycholesterol, guanidinosuccinic acid, and 5-hydroxyindolepyruvate.…”

Section: Discussionmentioning

confidence: 99%

Effects of Shenling Baizhu Powder on Pyrotinib-Induced Diarrhea: Analysis of Gut Microbiota, Metabonomics, and Network Pharmacology

Lai

Jiang

Zhuo

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Shenling Baizhu Powder (SBP) is a traditional Chinese medicine (TCM) prescription, which has good efficacy on gastrointestinal toxicity. In this study, we used gut microbiota analysis, metabonomics, and network pharmacology to investigate the therapeutic effect of SBP on pyrotinib-induced diarrhea. Methods 24 Rats were randomly divided into 4 groups: control group, SBP group (3.6 g/kg /bid SBP for 10 days), pyrotinib model group (80mg/kg/qd pyrotinib), and pyrotinib + SBP treatment group. A 16S rRNA sequencing was used to detect the microbiome of rat fecal bowel, metabolic profiles were collected by non-targeted metabolomics, and key metabolic pathways were identified using MetaboAnalyst 5.0. The antitumor effect of SBP on cells treated with pyrotinib was measured using a CCK-8 assay. Network pharmacology was used to predict the target and action pathway of SBP in treating pyrotinib-related diarrhea. Results In vivo study indicated that SBP could significantly alleviate pyrotinib-induced diarrhea, reaching a therapeutic effect of 66.7%. SBP could regulate pyrotinib-induced microbiota disorder. LEfSe research revealed that the SBP could potentially decrease the relative abundance of Escherichia, Helicobacter, and Enterobacteriaceae and increase the relative abundance of Lachnospiraceae, Bacilli, Lactobacillales etc. In addition, 25-Hydroxycholesterol, Guanidinosuccinic acid, 5-Hydroxyindolepyruvate, and cAMP were selected as potential biomarkers of SBP for pyrotinib-induced diarrhea. Moreover, Spearman's analysis showed a correlation between gut microbiota and metabolite: the decreased 25-hydroxycholesterol in the SBP treatment group was negatively correlated with Lachnospiraceae while positively correlated with Escherichia and Helicobacter. Meanwhile, SBP did not affect the inhibitory effect of pyrotinib on BT-474 cells and Calu-3 cells in vitro. Also, network analysis further revealed that SBP treated pyrotinib-induced diarrhea through multiple pathways, including inflammatory bowel disease, IL-17 signaling pathway, pathogenic Escherichia coli infection, and cAMP signaling pathway. Conclusions SBP could effectively relieve pyrotinib-induced diarrhea, revealing that intestinal flora and its metabolites may be involved in this process.

show abstract

Lachnospira is a signature of antihistamine efficacy in chronic spontaneous urticaria

Cited by 18 publications

References 24 publications

Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria

Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria

Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology

Effects of Shenling Baizhu Powder on Pyrotinib-Induced Diarrhea: Analysis of Gut Microbiota, Metabonomics, and Network Pharmacology

Contact Info

Product

Resources

About